SCHEMBL1697477

SCHEMBL1697477

CCOc1ccc(Br)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
NQO1 P15559 1/20 0.48
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46
TUBB2A Q13885 1/20 0.46
TUBB8 Q3ZCM7 1/20 0.46
TUBA3E Q6PEY2 1/20 0.46
TUBA1A Q71U36 1/20 0.46
TUBA1C Q9BQE3 1/20 0.46
TUBB6 Q9BUF5 1/20 0.46
TUBB2B Q9BVA1 1/20 0.46
TUBB1 Q9H4B7 1/20 0.46
ALDH1A1 P00352 1/20 0.45
HIF1A Q16665 1/20 0.43
DPP4 P27487 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5519840 0.88 KDM4E (0.56) KDM4ENQO1ALDH1A1CA12CA1
SCHEMBL30926069 0.88 KDM4E (0.56) KDM4ENQO1ALDH1A1CA12CA1
SCHEMBL164530 0.85 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL15919319 0.85 THRA (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL24993556 0.85 CA12 (0.47) KDM4ENQO1ALDH1A1ESR1AHR
SCHEMBL9425356 0.84 NQO1 (0.56) KDM4ENQO1ALDH1A1ESR1AHR
SCHEMBL2176515 0.83 FYN (0.45) KDM4EALDH1A1CA12CA1CA2
SCHEMBL30639283 0.83 FYN (0.45) KDM4EALDH1A1CA12CA1CA2
SCHEMBL9715643 0.82 CA2 (0.64) KDM4ENQO1TUBB4ATUBBTUBA3C
SCHEMBL22638161 0.81 MAPK1 (0.44) ALDH1A1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 WO disclosed
EP-2785690-B1 PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2016-07-13 EP disclosed
EP-2794586-B1 NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2016-04-20 EP disclosed
EP-2794587-B1 NEW PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2016-03-16 EP disclosed
EP-2588451-B1 PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INT (DE) 2015-12-30 EP disclosed
EP-2588451-B1 PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INT (DE) 2015-12-30 EP disclosed
US-20130158004-A1 Azetidine Derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130143876-A1 New piperidine derivatives, pharmaceutical compositions and uses thereof ROTH GERALD JUERGEN (DE) 2013-06-06 US disclosed
US-20130143876-A1 New piperidine derivatives, pharmaceutical compositions and uses thereof ROTH GERALD JUERGEN (DE) 2013-06-06 US disclosed
WO-2013079668-A1 PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-06 WO disclosed
EP-2588451-A1 PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS Boehringer Ingelheim International GmbH (DE) 2013-05-08 EP disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed
WO-2012001107-A1 PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-05 WO disclosed
WO-2012001107-A1 PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KDM4E 528/4885NQO1 1610/4885TUBB4A 1248/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B KDM4E 528/4885NQO1 1610/4885TUBB4A 1248/4885
US-20130143876-A1 New piperidine derivatives, pharmaceutical compositions and uses thereof P2RX5, PIR, P2RX4 KDM4E 1808/4885NQO1 1264/4885TUBB4A 672/4885
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF P2RX5, P2RX3, ABCG2 KDM4E 2840/4885NQO1 423/4885TUBB4A 421/4885
US-20130158004-A1 Azetidine Derivatives GPR119, LIPE, LPL KDM4E 1022/4885NQO1 1874/4885TUBB4A 3999/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KDM4E 773/4885NQO1 2235/4885TUBB4A 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.